Actively Recruiting

Phase 1
Age: 18Years +
MALE
NCT07545811

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Led by Janux Therapeutics · Updated on 2026-04-22

43

Participants Needed

1

Research Sites

150 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

CONDITIONS

Official Title

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male 18 years of age or older at the time of signing informed consent
  • Histologically or cytologically confirmed adenocarcinoma of the prostate
  • For Dose Escalation: Metastatic castration-resistant prostate cancer progressed after at least one novel anti-androgen therapy and at least one taxane-containing regimen, or medically unsuitable/refused taxane
  • Adequate organ function
  • For Dose Expansion: Received 2 or fewer anti-androgen therapies in hormone-sensitive or castration-resistant settings and no more than 1 prior taxane regimen in hormone-sensitive setting, or medically unsuitable/refused taxane
Not Eligible

You will not qualify if you...

  • Prior solid organ transplant
  • Prior treatment with any CAR-T cell therapy, approved or investigational T-cell engager therapy, or prior radioligand therapy
  • Clinically significant cardiovascular disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Research Site

Nashville, Tennessee, United States, 37203

Actively Recruiting

Loading map...

Research Team

J

Janux Therapeutics, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | DecenTrialz